Cargando…

Systemic Therapy of Non-Resectable Metastatic Melanoma

In advanced metastatic melanoma (non-resectable stage III/IV), the prognosis still remains poor, with median survival times between six and twelve months. Systemic therapeutic approaches for metastatic melanoma include chemotherapy, immunotherapy, immunochemotherapy, small molecules and targeted the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orouji, Azadeh, Goerdt, Sergij, Utikal, Jochen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835112/ https://www.ncbi.nlm.nih.gov/pubmed/24281101 http://dx.doi.org/10.3390/cancers2020955

Ejemplares similares

Tackling malignant melanoma epigenetically: histone lysine methylation
por: Orouji, Elias, et al.
Publicado: (2018)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
por: Reinhard, Raphael, et al.
Publicado: (2018)

Desmoglein 2 Depletion Leads to Increased Migration and Upregulation of the Chemoattractant Secretoneurin in Melanoma Cells
por: Peitsch, Wiebke K., et al.
Publicado: (2014)

Unique Role of Histone Methyltransferase PRDM8 in the Tumorigenesis of Virus-Negative Merkel Cell Carcinoma
por: Orouji, Elias, et al.
Publicado: (2020)

Oncogenic Role of an Epigenetic Reader of m(6)A RNA Modification: YTHDF1 in Merkel Cell Carcinoma
por: Orouji, Elias, et al.
Publicado: (2020)

Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern
por: Dietsch, Bianca, et al.
Publicado: (2023)

Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia: Case Report
por: Orouji, Elias, et al.
Publicado: (2014)

Human Chitinases and Chitinase-Like Proteins as Indicators for Inflammation and Cancer
por: Kzhyshkowska, Julia, et al.
Publicado: (2007)

New role of ID3 in melanoma adaptive drug-resistance
por: Sachindra,, et al.
Publicado: (2017)

Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response
por: Bernhardt, Mathias, et al.
Publicado: (2017)

Update on GNA Alterations in Cancer: Implications for Uveal Melanoma Treatment
por: Larribère, Lionel, et al.
Publicado: (2020)

Angiodiversity and organotypic functions of sinusoidal endothelial cells
por: Koch, Philipp-Sebastian, et al.
Publicado: (2021)

Stem Cell-Derived Models of Neural Crest Are Essential to Understand Melanoma Progression and Therapy Resistance
por: Larribère, Lionel, et al.
Publicado: (2019)

Melanoma Cellular Plasticity
por: Novak, Daniel, et al.
Publicado: (2022)

Systemic Therapy of Metastatic Melanoma: On the Road to Cure
por: Steininger, Julian, et al.
Publicado: (2021)

Cellular Reprogramming—A Model for Melanoma Cellular Plasticity
por: Granados, Karol, et al.
Publicado: (2020)

Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
por: Tsur, Neta, et al.
Publicado: (2019)

MYC gene amplification is a rare event in atypical fibroxanthoma and pleomorphic dermal sarcoma
por: Gaiser, Timo, et al.
Publicado: (2018)

Resection in the popliteal fossa for metastatic melanoma
por: Marone, Ugo, et al.
Publicado: (2007)

Complete Resection of Pulmonary Metastatic Melanoma
por: Kim, Jae Jun, et al.
Publicado: (2011)

NF1-Dependent Transcriptome Regulation in the Melanocyte Lineage and in Melanoma
por: Larribère, Lionel, et al.
Publicado: (2021)

Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapies
por: Hüser, Laura, et al.
Publicado: (2019)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Molecular targeted therapies in metastatic melanoma
por: Chakraborty, Rima, et al.
Publicado: (2013)

Non-pegylated and Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma and the Risk of Severe Ocular Side-effects
por: ALBRECHT, Jana D., et al.
Publicado: (2022)

A Review of Novel Systemic Therapies and Brain Radiosurgery for Metastatic Melanoma
por: Overbay, Dexter A, et al.
Publicado: (2012)

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
por: Ozbay Kurt, Feyza Gul, et al.
Publicado: (2023)

Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human Melanoblasts
por: Larribère, Lionel, et al.
Publicado: (2018)

Expression of Osteoarthritis Marker YKL-39 is Stimulated by Transforming Growth Factor Beta (TGF-beta) and IL-4 in Differentiating Macrophages
por: Gratchev, Alexei, et al.
Publicado: (2008)

Therapy for metastatic melanoma: the past, present, and future
por: Finn, Laura, et al.
Publicado: (2012)

Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study
por: Nicolay, Jan P., et al.
Publicado: (2023)

Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)
por: Hassel, Jessica C., et al.
Publicado: (2017)

Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment
por: Kromer, Christian, et al.
Publicado: (2015)

Trametinib: A Targeted Therapy in Metastatic Melanoma
por: Hoffner, Brianna, et al.
Publicado: (2018)

Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma
por: Vennepureddy, Adarsh, et al.
Publicado: (2016)

Photodynamic Therapy for Metastatic Melanoma Treatment: A Review
por: Naidoo, Channay, et al.
Publicado: (2018)

TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma
por: Strobel, Sophia B., et al.
Publicado: (2022)

Nanoparticle-Based Drug Delivery Systems for Photodynamic Therapy of Metastatic Melanoma: A Review
por: Nkune, Nkune Williams, et al.
Publicado: (2021)

Analysis of Demographics and Outcomes of Surgical Resection in the Central Nervous System of Patients With Metastatic Melanoma
por: Guddati, Achuta Kumar, et al.
Publicado: (2021)

Case report: Therapeutic potential of T-VEC in combination with MEK inhibitors in melanoma patients with NRAS mutation
por: Simon, Sonja C. S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lsc20qpldeer5k7vj04f1ltm00